LONA LeonaBio Inc.

  1. Stocks
  2. Healthcare
  3. NASDAQ: LONA

Price (delayed)

$5.89

Market cap

$55.49M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$23.11

Enterprise value

$23.12M

?
Relative Growth: Rel. Growth: 6
Relative Strength: Rel. Strength: 24
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 0

Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to alter ...

Highlights
The company's debt fell by 43% YoY and by 16% QoQ
The EPS is down by 50% YoY but it is up by 4.1% QoQ
LONA's equity is down by 32% from the previous quarter but it is up by 5% YoY
LONA's net income has dropped by 136% year-on-year and by 9% since the previous quarter
LONA's quick ratio is down by 36% from the previous quarter and by 35% YoY
Sector: Healthcare
Industry: Biotechnology
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of LONA

LONA stock price

How has the LeonaBio stock price performed over time
Intraday
-2.64%
1 week
-13.25%
1 month
-23.36%
1 year
39.9%
YTD
-22.19%
QTD
-35.91%

Financial performance

How have LeonaBio's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$122.11M
Net income
-$141.46M
Gross margin
N/A
Net margin
N/A
LONA's net income has dropped by 136% year-on-year and by 9% since the previous quarter
LONA's operating income has plunged by 97% YoY and by 11% from the previous quarter

Price vs fundamentals

How does LONA's price correlate with its fundamentals

Growth

What is LeonaBio's growth rate over time

Valuation

What is LeonaBio stock price valuation
P/E
N/A
P/B
1.65
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is down by 50% YoY but it is up by 4.1% QoQ
LONA's P/B is 88% above its 5-year quarterly average of 0.9 and 6% above its last 4 quarters average of 1.6
LONA's equity is down by 32% from the previous quarter but it is up by 5% YoY

Efficiency

How efficient is LeonaBio business performance
LONA's return on equity has dropped by 195% year-on-year and by 8% since the previous quarter
LeonaBio's ROA has plunged by 111% YoY
The ROIC has soared by 58% YoY and by 3.5% from the previous quarter

Dividends

What is LONA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LONA.

Financial health

How did LeonaBio financials performed over time
The total assets is 144% greater than the total liabilities
The total assets has soared by 60% year-on-year but it has declined by 21% since the previous quarter
LONA's quick ratio is down by 36% from the previous quarter and by 35% YoY
The company's debt is 98% lower than its equity
The company's debt to equity has surged by 100% QoQ but it fell by 33% YoY
The company's debt fell by 43% YoY and by 16% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.